Results from Phil's 2017 Clinical Drug Study
In 2017 Phil participated in a 7-month clinical drug study (SUVN-502) aimed at Alzheimer's patients in the moderate stage. In June, 2017 he barely qualified.
This was a double blind study. The meds were one of the following: placebo, 50 mg, or 100 mg of the research medicine. The object was to improve cognition.
This month the study was closed and unblinded. Phil was on the 50 mg dose. He had no negative side effects and he also showed no improvement. Other patients saw improvement, but some side effects.
Phase 3 is opening up, but not in any San Antonio locations.
Dr. Thomas Weiss, the psychiatrist who ran the study, in his effort to continue to study Alzheimer's Disease, has now moved to Clinical Trials of Texas. This company conducts Phase 4 studies on many diseases, including AD. At their website you can sign up for a free memory screening.
Clinical studies take time, won't help our loved ones, but will help someone in the future. Maybe someone you love.
Thank youfor sharing the information with the picture. Now I feel like I know Phil when you talk about him. Praying for good result from the next study.